AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used in Clinical Diagnostic Kits

10-Jul-2009 - Spain

MorphoSys AG announced that its research and diagnostic antibody segment AbD Serotec and Spinreact S.A. have signed a supply agreement. Initially, the agreement covers the use of two antibodies which Spinreact will incorporate in a series of clinical diagnostic kits. AbD Serotec will continuously supply Spinreact with antibody material. Financial details of the agreement were not disclosed.

Dr Josep Puig, Chief Executive Officer of Spinreact, said: "The fast turn-around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of development and validation, allowing Spinreact to bring new clinical diagnostic reagents for human diseases to the market in the shortest possible timeframe."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous